MyPath: Developing and implementing innovative Patient-Centred Care Pathways for cancer patients

在欧盟，2020年有270万人被诊断患有癌症，130万人死于癌症。由于早期检测和新疗法的进步，超过1200万人从癌症中幸存下来。随着治愈率的提高和癌症患者寿命的延长，获得以患者为中心的护理，包括最佳支持、姑息治疗、生存和临终关怀，变得越来越重要。然而，癌症治疗仍然存在孤岛，直到今天，还没有适合不同文化、环境和环境的技术支持。一些随机对照试验提供了证据，证明在标准肿瘤治疗中整合以患者为中心的治疗可以改善患者和护理人员的预后。到目前为止，这些发现还没有转化为临床常规。在这个项目中，我们将开发技术增强和基于证据的以患者为中心的护理途径，称为MyPath，将其与肿瘤为中心的治疗相结合，包括支持性、姑息性、生存和临终关怀。在英国，我们已经在随机对照试验的背景下，在19个区域癌症中心整合了癌症疼痛评估和管理途径的经验。这一结果是积极的，并证明了临床医生在与所有患者交谈时使用简单，一致和清晰的语言，可以以非常积极的方式改变护理。虽然MyPath是一项复杂的研究，但我们的目标是通过简单、一致和清晰的途径实现的目标一点也不复杂，应该会大大改善癌症患者的护理和护理公平性。MyPath整合了us Eir软件的患者报告结果，并在欧洲知名肿瘤学家、伦理学家、心理学家和社会学家的贡献下进一步发展。它将在我们的中小企业合作伙伴DNV Imatis的eHealth平台上配置。它的有效性和可持续性将在欧洲9个临床中心的实施科学研究中进行评估。在领先的癌症护理专业协会ESMO和EAPC以及癌症患者组织ECPC的支持下，我们致力于在合适的时间由合适的人向合适的人提供合适的护理。我们假设MyPath可以显著提高治疗和护理的质量和可及性，减少临床实践中的变化，并优化家庭、社区和医院护理环境中的资源。这将最终减轻与癌症相关的身体、情感和经济负担。在欧盟，2020年有270万人被诊断出患有癌症，130万人死于癌症。由于早期检测和新疗法的进步，超过1200万人从癌症中幸存下来。随着治愈率的提高和癌症患者寿命的延长，获得以患者为中心的护理，包括最佳支持、姑息治疗、生存和临终关怀，变得越来越重要。然而，癌症治疗仍然存在孤岛，直到今天，还没有适合不同文化、环境和环境的技术支持。一些随机对照试验提供了证据，证明在标准肿瘤治疗中整合以患者为中心的治疗可以改善患者和护理人员的预后。到目前为止，这些发现还没有转化为临床常规。在这个项目中，我们将开发技术增强和基于证据的以患者为中心的护理途径，称为MyPath，将其与肿瘤为中心的治疗相结合，包括支持性、姑息性、生存和临终关怀。在英国，我们已经在随机对照试验的背景下，在19个区域癌症中心整合了癌症疼痛评估和管理途径的经验。这一结果是积极的，并证明了临床医生在与所有患者交谈时使用简单，一致和清晰的语言，可以以非常积极的方式改变护理。虽然MyPath是一项复杂的研究，但我们的目标是通过简单、一致和清晰的途径实现的目标一点也不复杂，应该会大大改善癌症患者的护理和护理公平性。MyPath整合了us Eir软件的患者报告结果，并在欧洲知名肿瘤学家、伦理学家、心理学家和社会学家的贡献下进一步发展。它将在我们的中小企业合作伙伴DNV Imatis的eHealth平台上配置。它的有效性和可持续性将在欧洲9个临床中心的实施科学研究中进行评估。在领先的癌症护理专业协会ESMO和EAPC以及癌症患者组织ECPC的支持下，我们致力于在合适的时间由合适的人向合适的人提供合适的护理。我们假设MyPath可以显著提高治疗和护理的质量和可及性，减少临床实践中的变化，并优化家庭、社区和医院护理环境中的资源。这将最终减轻与癌症相关的身体、情感和经济负担。在欧盟，2020年有270万人被诊断出患有癌症，130万人死于癌症。由于早期检测和新疗法的进步，超过1200万人从癌症中幸存下来。随着治愈率的提高和癌症患者寿命的延长，获得以患者为中心的护理，包括最佳支持、姑息治疗、生存和临终关怀，变得越来越重要。然而，癌症治疗仍然存在孤岛，直到今天，还没有适合不同文化、环境和环境的技术支持。一些随机对照试验提供了证据，证明在标准肿瘤治疗中整合以患者为中心的治疗可以改善患者和护理人员的预后。到目前为止，这些发现还没有转化为临床常规。在这个项目中，我们将开发技术增强和基于证据的以患者为中心的护理途径，称为MyPath，将其与肿瘤为中心的治疗相结合，包括支持性、姑息性、生存和临终关怀。在英国，我们已经在随机对照试验的背景下，在19个区域癌症中心整合了癌症疼痛评估和管理途径的经验。这一结果是积极的，并证明了临床医生在与所有患者交谈时使用简单，一致和清晰的语言，可以以非常积极的方式改变护理。虽然MyPath是一项复杂的研究，但我们的目标是通过简单、一致和清晰的途径实现的目标一点也不复杂，应该会大大改善癌症患者的护理和护理公平性。MyPath整合了us Eir软件的患者报告结果，并在欧洲知名肿瘤学家、伦理学家、心理学家和社会学家的贡献下进一步发展。它将在我们的中小企业合作伙伴DNV Imatis的eHealth平台上配置。它的有效性和可持续性将在欧洲9个临床中心的实施科学研究中进行评估。在领先的癌症护理专业协会ESMO和EAPC以及癌症患者组织ECPC的支持下，我们致力于在合适的时间由合适的人向合适的人提供合适的护理。我们假设MyPath可以显著提高治疗和护理的质量和可及性，减少临床实践中的变化，并优化家庭、社区和医院护理环境中的资源。这将最终减轻与癌症相关的身体、情感和经济负担。在欧盟，2020年有270万人被诊断出患有癌症，130万人死于癌症。由于早期检测和新疗法的进步，超过1200万人从癌症中幸存下来。随着治愈率的提高和癌症患者寿命的延长，获得以患者为中心的护理，包括最佳支持、姑息治疗、生存和临终关怀，变得越来越重要。然而，癌症治疗仍然存在孤岛，直到今天，还没有适合不同文化、环境和环境的技术支持。一些随机对照试验提供了证据，证明在标准肿瘤治疗中整合以患者为中心的治疗可以改善患者和护理人员的预后。到目前为止，这些发现还没有转化为临床常规。在这个项目中，我们将开发技术增强和基于证据的以患者为中心的护理途径，称为MyPath，将其与肿瘤为中心的治疗相结合，包括支持性、姑息性、生存和临终关怀。在英国，我们已经在随机对照试验的背景下，在19个区域癌症中心整合了癌症疼痛评估和管理途径的经验。这一结果是积极的，并证明了临床医生在与所有患者交谈时使用简单，一致和清晰的语言，可以以非常积极的方式改变护理。虽然MyPath是一项复杂的研究，但我们的目标是通过简单、一致和清晰的途径实现的目标一点也不复杂，应该会大大改善癌症患者的护理和护理公平性。MyPath整合了us Eir软件的患者报告结果，并在欧洲知名肿瘤学家、伦理学家、心理学家和社会学家的贡献下进一步发展。它将在我们的中小企业合作伙伴DNV Imatis的eHealth平台上配置。它的有效性和可持续性将在欧洲9个临床中心的实施科学研究中进行评估。在领先的癌症护理专业协会ESMO和EAPC以及癌症患者组织ECPC的支持下，我们致力于在合适的时间由合适的人向合适的人提供合适的护理。我们假设MyPath可以显著提高治疗和护理的质量和可及性，减少临床实践中的变化，并优化家庭、社区和医院护理环境中的资源。这将最终减轻与癌症相关的身体、情感和经济负担。在欧盟，2020年有270万人被诊断出患有癌症，130万人死于癌症。由于早期检测和新疗法的进步，超过1200万人从癌症中幸存下来。随着治愈率的提高和癌症患者寿命的延长，获得以患者为中心的护理，包括最佳支持、姑息治疗、生存和临终关怀，变得越来越重要。然而，癌症治疗仍然存在孤岛，直到今天，还没有适合不同文化、环境和环境的技术支持。一些随机对照试验提供了证据，证明在标准肿瘤治疗中整合以患者为中心的治疗可以改善患者和护理人员的预后。到目前为止，这些发现还没有转化为临床常规。在这个项目中，我们将开发技术增强和基于证据的以患者为中心的护理途径，称为MyPath，将其与肿瘤为中心的治疗相结合，包括支持性、姑息性、生存和临终关怀。在英国，我们已经在随机对照试验的背景下，在19个区域癌症中心整合了癌症疼痛评估和管理途径的经验。这一结果是积极的，并证明了临床医生在与所有患者交谈时使用简单，一致和清晰的语言，可以以非常积极的方式改变护理。虽然MyPath是一项复杂的研究，但我们的目标是通过简单、一致和清晰的途径实现的目标一点也不复杂，应该会大大改善癌症患者的护理和护理公平性。MyPath整合了us Eir软件的患者报告结果，并在欧洲知名肿瘤学家、伦理学家、心理学家和社会学家的贡献下进一步发展。它将在我们的中小企业合作伙伴DNV Imatis的eHealth平台上配置。它的有效性和可持续性将在欧洲9个临床中心的实施科学研究中进行评估。在领先的癌症护理专业协会ESMO和EAPC以及癌症患者组织ECPC的支持下，我们致力于在合适的时间由合适的人向合适的人提供合适的护理。我们假设MyPath可以显著提高治疗和护理的质量和可及性，减少临床实践中的变化，并优化家庭、社区和医院护理环境中的资源。这将最终减少与癌症相关的身体、情感和经济负担

In the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanks to advances in early detection and new therapies. With higher cure rates and more patients living longer with cancer, access to patient-centred care consisting of optimal supportive, palliative, survivorship and end-of-life care becomes increasingly important. However, cancer care still has silos, and to this day, there is no technical support available that is suitable for different cultures, settings and environments. Several randomised controlled trials have provided evidence that the integration of patient-centred care in standard oncology care results in better patient and caregiver outcomes. As yet, these findings have not translated into clinical routine. In this project, we will develop technology-enhanced and evidence-based patient-centred care pathways, called MyPath, to be merged with tumour-centred treatments across supportive, palliative, survivorship and end-of-life care. In the UK we already have experience of the integration of cancer pain assessment and management pathway in 19 regional cancer centres within the context of a randomised controlled trial. The outcome of this was positive and demonstrated that the use of simple, consistent and clear language used by clinicians when speaking with all patients, can transform care in a very positive way. While MyPath is a complex study, what we aim to achieve with simple consistent and clear pathways is not at all complicated and should lead to much improved care and equity of care for cancer patients. MyPath integrates patient-reported outcomes of the OUS Eir software, to be further advanced with contributions of renowned European oncologists, ethicists, psychologists and sociologists. It will be configurated on the eHealth platform of our SME partner DNV Imatis. Its effectiveness and sustainability will be assessed in an implementation science study in 9 clinical centres across Europe. With the support of leading cancer care professional associations ESMO and EAPC, and the cancer patient organisation ECPC, we are committed to delivering the right care to the right person at the right time by the right persons. We hypothesise that MyPath can significantly improve the quality of and access to treatment and care, reduce variations in clinical practice, and optimise resources in family, community, and hospital care settings. This will ultimately reduce the physical, emotional, and ultimately economic burden linked to cancerIn the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanks to advances in early detection and new therapies. With higher cure rates and more patients living longer with cancer, access to patient-centred care consisting of optimal supportive, palliative, survivorship and end-of-life care becomes increasingly important. However, cancer care still has silos, and to this day, there is no technical support available that is suitable for different cultures, settings and environments. Several randomised controlled trials have provided evidence that the integration of patient-centred care in standard oncology care results in better patient and caregiver outcomes. As yet, these findings have not translated into clinical routine. In this project, we will develop technology-enhanced and evidence-based patient-centred care pathways, called MyPath, to be merged with tumour-centred treatments across supportive, palliative, survivorship and end-of-life care. In the UK we already have experience of the integration of cancer pain assessment and management pathway in 19 regional cancer centres within the context of a randomised controlled trial. The outcome of this was positive and demonstrated that the use of simple, consistent and clear language used by clinicians when speaking with all patients, can transform care in a very positive way. While MyPath is a complex study, what we aim to achieve with simple consistent and clear pathways is not at all complicated and should lead to much improved care and equity of care for cancer patients. MyPath integrates patient-reported outcomes of the OUS Eir software, to be further advanced with contributions of renowned European oncologists, ethicists, psychologists and sociologists. It will be configurated on the eHealth platform of our SME partner DNV Imatis. Its effectiveness and sustainability will be assessed in an implementation science study in 9 clinical centres across Europe. With the support of leading cancer care professional associations ESMO and EAPC, and the cancer patient organisation ECPC, we are committed to delivering the right care to the right person at the right time by the right persons. We hypothesise that MyPath can significantly improve the quality of and access to treatment and care, reduce variations in clinical practice, and optimise resources in family, community, and hospital care settings. This will ultimately reduce the physical, emotional, and ultimately economic burden linked to cancerIn the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanks to advances in early detection and new therapies. With higher cure rates and more patients living longer with cancer, access to patient-centred care consisting of optimal supportive, palliative, survivorship and end-of-life care becomes increasingly important. However, cancer care still has silos, and to this day, there is no technical support available that is suitable for different cultures, settings and environments. Several randomised controlled trials have provided evidence that the integration of patient-centred care in standard oncology care results in better patient and caregiver outcomes. As yet, these findings have not translated into clinical routine. In this project, we will develop technology-enhanced and evidence-based patient-centred care pathways, called MyPath, to be merged with tumour-centred treatments across supportive, palliative, survivorship and end-of-life care. In the UK we already have experience of the integration of cancer pain assessment and management pathway in 19 regional cancer centres within the context of a randomised controlled trial. The outcome of this was positive and demonstrated that the use of simple, consistent and clear language used by clinicians when speaking with all patients, can transform care in a very positive way. While MyPath is a complex study, what we aim to achieve with simple consistent and clear pathways is not at all complicated and should lead to much improved care and equity of care for cancer patients. MyPath integrates patient-reported outcomes of the OUS Eir software, to be further advanced with contributions of renowned European oncologists, ethicists, psychologists and sociologists. It will be configurated on the eHealth platform of our SME partner DNV Imatis. Its effectiveness and sustainability will be assessed in an implementation science study in 9 clinical centres across Europe. With the support of leading cancer care professional associations ESMO and EAPC, and the cancer patient organisation ECPC, we are committed to delivering the right care to the right person at the right time by the right persons. We hypothesise that MyPath can significantly improve the quality of and access to treatment and care, reduce variations in clinical practice, and optimise resources in family, community, and hospital care settings. This will ultimately reduce the physical, emotional, and ultimately economic burden linked to cancerIn the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanks to advances in early detection and new therapies. With higher cure rates and more patients living longer with cancer, access to patient-centred care consisting of optimal supportive, palliative, survivorship and end-of-life care becomes increasingly important. However, cancer care still has silos, and to this day, there is no technical support available that is suitable for different cultures, settings and environments. Several randomised controlled trials have provided evidence that the integration of patient-centred care in standard oncology care results in better patient and caregiver outcomes. As yet, these findings have not translated into clinical routine. In this project, we will develop technology-enhanced and evidence-based patient-centred care pathways, called MyPath, to be merged with tumour-centred treatments across supportive, palliative, survivorship and end-of-life care. In the UK we already have experience of the integration of cancer pain assessment and management pathway in 19 regional cancer centres within the context of a randomised controlled trial. The outcome of this was positive and demonstrated that the use of simple, consistent and clear language used by clinicians when speaking with all patients, can transform care in a very positive way. While MyPath is a complex study, what we aim to achieve with simple consistent and clear pathways is not at all complicated and should lead to much improved care and equity of care for cancer patients. MyPath integrates patient-reported outcomes of the OUS Eir software, to be further advanced with contributions of renowned European oncologists, ethicists, psychologists and sociologists. It will be configurated on the eHealth platform of our SME partner DNV Imatis. Its effectiveness and sustainability will be assessed in an implementation science study in 9 clinical centres across Europe. With the support of leading cancer care professional associations ESMO and EAPC, and the cancer patient organisation ECPC, we are committed to delivering the right care to the right person at the right time by the right persons. We hypothesise that MyPath can significantly improve the quality of and access to treatment and care, reduce variations in clinical practice, and optimise resources in family, community, and hospital care settings. This will ultimately reduce the physical, emotional, and ultimately economic burden linked to cancerIn the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanks to advances in early detection and new therapies. With higher cure rates and more patients living longer with cancer, access to patient-centred care consisting of optimal supportive, palliative, survivorship and end-of-life care becomes increasingly important. However, cancer care still has silos, and to this day, there is no technical support available that is suitable for different cultures, settings and environments. Several randomised controlled trials have provided evidence that the integration of patient-centred care in standard oncology care results in better patient and caregiver outcomes. As yet, these findings have not translated into clinical routine. In this project, we will develop technology-enhanced and evidence-based patient-centred care pathways, called MyPath, to be merged with tumour-centred treatments across supportive, palliative, survivorship and end-of-life care. In the UK we already have experience of the integration of cancer pain assessment and management pathway in 19 regional cancer centres within the context of a randomised controlled trial. The outcome of this was positive and demonstrated that the use of simple, consistent and clear language used by clinicians when speaking with all patients, can transform care in a very positive way. While MyPath is a complex study, what we aim to achieve with simple consistent and clear pathways is not at all complicated and should lead to much improved care and equity of care for cancer patients. MyPath integrates patient-reported outcomes of the OUS Eir software, to be further advanced with contributions of renowned European oncologists, ethicists, psychologists and sociologists. It will be configurated on the eHealth platform of our SME partner DNV Imatis. Its effectiveness and sustainability will be assessed in an implementation science study in 9 clinical centres across Europe. With the support of leading cancer care professional associations ESMO and EAPC, and the cancer patient organisation ECPC, we are committed to delivering the right care to the right person at the right time by the right persons. We hypothesise that MyPath can significantly improve the quality of and access to treatment and care, reduce variations in clinical practice, and optimise resources in family, community, and hospital care settings. This will ultimately reduce the physical, emotional, and ultimately economic burden linked to cancer